Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
9 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A mechanistic computational model of checkpoint-inhibitor combinations in mice that predicts synergy but lacks experimental validation of the proposed mechanisms in humans and does not address clinical efficacy or safety.
A single-centre RCT with adequate design and clear positive primary endpoint results, but limited by modest sample size, short follow-up, and generalizability to one setting in China.
This is an early-stage preclinical study demonstrating proof-of-concept for a novel theranostic nanoparticle in mouse models of TNBC, with no human data, no clinical outcomes, and no comparison to standard surgical or immunotherapeutic approaches.
A retrospective cohort study with sound paired-kidney design isolating donor and recipient risk factors for delayed graft function, but limited by single-centre recruitment and lack of prospective validation.
Small single-center matched cohort study (31 per group) with retrospective design and surrogate endpoints; findings on concurrent nephropathy and renal function decline are clinically relevant but require validation in larger prospective studies.
This is a single-centre retrospective descriptive study reporting epidemiological frequencies and patterns without a control group, comparison arm, or hypothesis testing; it characterizes disease occurrence but does not establish causation, prognosis, or intervention efficacy.
A novel methodological proposal with algorithmic validation on semi-synthetic and industrial observational data, but without peer review, no confirmatory RCT of the full method, and results presented as descriptive frontier consistency rather than independent statistical significance.
Mechanistic study in animal models of a proposed metabolic axis in lung cancer bone metastasis; no clinical outcome data, human efficacy trials, or direct comparison to standard therapy reported.